Bridgebio Pharma Inc (BBIO) cash flow statement

NASDAQ · Health Care

$76.80 -0.72% Close Nov 17, 2026 Live

TrendArc score 42 of 100 · Health 1.7 · Momentum 6.8 · Moat 3.9 · scored Nov 17, 2026 · How the score works

Free cash flow, fiscal year to December 31, 2025

-$447 million

against -$522 million the year before

In the fiscal year to December 2025, Bridgebio Pharma used $446 million in its operations and spent $1 million on capital spending, a free cash flow of -$447 million. That was -89.0% of revenue, against -235.1% the year before. Over the last four quarters, to September 30, 2026, it was -$370 million.

What stands out

  • Diluted shares outstanding rose 62.3% over the five fiscal years to December 2025.

Each sentence is written by a fixed rule from the figures on this page.

Free cash flow and net income, the last 9 fiscal years

-$800M-$600M-$400M-$200M$200M$400M$600M$800M201720182019202020212022202320242025-$41.0MFree cash flow -$447MNet income -$725M-$800M-$600M-$400M-$200M$200M$400M$600M$800M20172019202120232025Free cash flow -$447MNet income -$725M

Fiscal years, each labelled by the calendar year it ended in. Every figure is in the statement below.

Cash flow statement, the last 9 fiscal years

In millions of US dollars. Each column is a fiscal year, named by the month it ended; the first column adds up the last four quarters. Cash paid out is a negative number.
Fiscal year toLast 4 quarters
to Sep 2026
Dec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating activities
Net income-725-536-643-481-563-449-261-131-31
Depreciation and amortisation101011121151——
Stock-based pay1521339610992100582162
Working capital and other items136-91-4-42-46-14-15——
Cash from operations-369-446-521-528-419-498-400-254-137-40
Investing activities
Capital spending-1-1-1-1105-13-8-3-20
Businesses bought and sold, net00-1101400-190
Investments bought and sold, net-157056339-166-39-21300
Other investing-8-80-2-35-7-200
Cash from investing-246154453-201-53-217-210
Financing activities
Debt issued or repaid, net4014330-201,06453737564
Shares issued less bought back-264-563124466-201-75367960
Dividends paid0000000000
Other financing14452-126-15-5350109
Cash from financing359748452-13736447399502113
Net change in cash-111289-222138-6-7234472
Free cash flow
Free cash flow-370-447-522-529—a-511-407-256-139-41
Free cash flow margin-39.1%-89.0%-235.1%-5686.6%—-733.2%-4936.7%-631.7%——
Free cash flow per share-$2.33-$2.80-$3.25—-$3.54-$3.45-$2.44-$2.25-$1.34
Free cash flow less stock-based pay-580-617-638—-611-466-278-145-43

a: capital spending was positive that year (the company sold more property and equipment than it bought), so no free cash flow is shown.

Shares issued less bought back is the cash from shares sold less the cash paid for shares bought back (negative when more was bought back), and includes tax withheld when employees' shares vest. Working capital and other items is cash from operations less net income, depreciation and amortisation, and stock-based pay (calculated by TrendArc). Company filings as standardised by Tiingo; calculations by TrendArc. Rebuilt nightly.

Bridgebio Pharma against its peers

CompanyFiscal year toFree cash flowFree cash flow margin
ExelixisEXEL Dec 2025$876M37.7%
RevvityRVTY Dec 2025$509M17.8%
Charles River LaboratoriesCRL Dec 2025$518M12.9%
Cooper Companies (The)COO Oct 2025$434M10.6%
Brightspring Health ServicesBTSG Dec 2025$395M3.1%
Baxter InternationalBAX Dec 2025$323M2.9%
SolventumSOLV Dec 2025-$10.0M-0.1%
GlaukosGKOS Dec 2025-$39.1M-7.7%
Bridgebio PharmaBBIO Dec 2025-$447M-89.0%
Peer median6.8%

Each company's newest fiscal year; some end in other months. The peers are the stock card's peer group.

Next

Follow Bridgebio Pharma with a free account.

A watchlist, price alerts and saved chart layouts. No card needed.

Sign up free

No forecast, no recommendation. This page describes Bridgebio Pharma Inc from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.